低剂量PARP抑制剂放疗化疗联合试验中改进的药效学评估
研究开发了基于离体照射增强PAR信号的REP药效学检测法,用于评估低浓度PARP抑制剂的活性。该方法在健康个体和接受奥拉帕利联合放疗的肺癌患者中验证,可灵敏检测PARP抑制并揭示个体差异,在低每日剂量下证实了临床相关的细胞PARP抑制活性。
要点
- REP检测法通过离体照射放大PAR信号,扩展了PARP抑制活性的定量范围。
- REP法可准确测定IC50并揭示健康个体间的差异。
- 在奥拉帕利联合放疗的肺癌患者中,REP法灵敏检测到低每日剂量下的强PARP抑制活性。
核心结论
- 放疗与新型靶向药物联合试验需要比单药治疗更灵敏的药效学评估,REP检测法为此类联合治疗提供了灵敏且适应性强的药效学评估手段。
研究设计与样本
- 收集健康个体及接受奥拉帕利和放疗的肺癌患者的外周血单核细胞,进行基于ELISA的药效学检测。
主要发现
- 离体照射增强PAR信号,使REP检测法扩展了PARP抑制活性的定量范围。
- REP检测法提供了准确的IC50值,并揭示了健康个体间的差异。
- 在临床放疗联合I期试验中,REP检测法灵敏检测到接受奥拉帕利治疗患者的PARP抑制,并证实低每日剂量下具有强PARP抑制活性。
临床怎么用
- 在放疗联合靶向药物的临床试验中,可采用REP检测法进行灵敏的药效学评估,以检测低剂量PARP抑制剂的活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PARP inhibitors are currently evaluated in combination with radiotherapy and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations therefore requiring highly sensitive pharmacodynamic (PD) assays. Current clinical PD-assays partly fail to provide such sensitivities. The aim of our study was to enable sensitive PD evaluation of PARP inhibitors for clinical sensitizer development. MATERIAL AND METHODS: PBMCs of healthy individuals and of olaparib and radiotherapy treated lung cancer patients were collected for ELISA-based PD-assays. RESULTS: PAR-signal amplification by ex vivo irradiation enabled an extended quantification range for PARP inhibitory activities after ex vivo treatment with inhibitors. This "radiation-enhanced-PAR" (REP) assay provided accurate IC50 values thereby also revealing differences among healthy individuals. Implemented in clinical radiotherapy combination Phase I trials, the REP-assay showed sensitive detection of PARP inhibition in patients treated with olaparib and establishes strong PARP inhibitory activities at low daily doses. CONCLUSIONS: Combination trials of radiotherapy and novel targeted agent(s) often require different and more sensitive PD assessments than in the monotherapy setting. This study shows the benefit and relevance of sensitive and adapted PD-assays for such combination purposes and provides proof of clinically relevant cellular PARP inhibitory activities at low daily olaparib doses.
引用
- de Haan R, Pluim D, van Triest B, et al. Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials. Radiother Oncol. 2017. PMID: 29150161. doi:10.1016/j.radonc.2017.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。